OBJECTIVE: The most popular surgical method for deep brain stimulation (DBS) in Parkinson's disease (PD) is simultaneous bilateral DBS. However, some centers conduct a staged unilateral approach advocating that reduced continuous intraoperative time reduces postoperative complications, thus justifying the cost of a second operative session. To test these assumptions, we performed a retrospective analysis of the Truven Health MarketScan® Database. METHODS: Using the MarketScan Database, we retrospectively analyzed patients that underwent simultaneous bilateral or staged unilateral DBS between 2000 and 2009. The main outcome measures were 90-day postoperative complication rates, number of reprogramming hours one year following procedure, and annualized healthcare cost. The outcome measures were compared between cohorts using multivariate regressions controlling for appropriate covariates. RESULTS: A total of 713 patients that underwent DBS between 2000 and 2009 met inclusion criteria for the study. Of these patients, 556 underwent simultaneous bilateral DBS and 157 received staged unilateral DBS. No statistically significant differences were found between groups in the rate of infection (simultaneous: 4.3% vs. staged: 7.0%; p = 0.178), pneumonia (3.1% vs. 5.7%; p = 0.283), hemorrhage (2.9% vs. 2.5%; p = 0.844), pulmonary embolism (0.5% vs. 1.3%), and device-related complications (0.5% vs. 0.0%). Patients in the staged cohort had a higher rate of lead revision in 90 days (3.2% vs. 12.7%; RR = 3.07; p < 0.001). The staged cohort had a higher mean (SD) number of reprogramming hours within one year of procedure (6.0 ± 5.7 vs. 7.8 ± 8.1; RR = 1.17; p < 0.001). No significant difference was found between the mean (SD) annualized payments between the cohorts ($86,100 ± $94,700 vs. $102,100 ± $121,500; p = 0.148). CONCLUSION: Our study did not find a significant difference between 90-day postoperative complication rates or annualized cost between the staged and simultaneous cohorts. Thus, we believe that it is important to consider other factors when deciding between the staged and simultaneous DBS. Such factors include patient convenience and the laterality of symptoms.
OBJECTIVE: The most popular surgical method for deep brain stimulation (DBS) in Parkinson's disease (PD) is simultaneous bilateral DBS. However, some centers conduct a staged unilateral approach advocating that reduced continuous intraoperative time reduces postoperative complications, thus justifying the cost of a second operative session. To test these assumptions, we performed a retrospective analysis of the Truven Health MarketScan® Database. METHODS: Using the MarketScan Database, we retrospectively analyzed patients that underwent simultaneous bilateral or staged unilateral DBS between 2000 and 2009. The main outcome measures were 90-day postoperative complication rates, number of reprogramming hours one year following procedure, and annualized healthcare cost. The outcome measures were compared between cohorts using multivariate regressions controlling for appropriate covariates. RESULTS: A total of 713 patients that underwent DBS between 2000 and 2009 met inclusion criteria for the study. Of these patients, 556 underwent simultaneous bilateral DBS and 157 received staged unilateral DBS. No statistically significant differences were found between groups in the rate of infection (simultaneous: 4.3% vs. staged: 7.0%; p = 0.178), pneumonia (3.1% vs. 5.7%; p = 0.283), hemorrhage (2.9% vs. 2.5%; p = 0.844), pulmonary embolism (0.5% vs. 1.3%), and device-related complications (0.5% vs. 0.0%). Patients in the staged cohort had a higher rate of lead revision in 90 days (3.2% vs. 12.7%; RR = 3.07; p < 0.001). The staged cohort had a higher mean (SD) number of reprogramming hours within one year of procedure (6.0 ± 5.7 vs. 7.8 ± 8.1; RR = 1.17; p < 0.001). No significant difference was found between the mean (SD) annualized payments between the cohorts ($86,100 ± $94,700 vs. $102,100 ± $121,500; p = 0.148). CONCLUSION: Our study did not find a significant difference between 90-day postoperative complication rates or annualized cost between the staged and simultaneous cohorts. Thus, we believe that it is important to consider other factors when deciding between the staged and simultaneous DBS. Such factors include patient convenience and the laterality of symptoms.
Authors: Michael R DeLong; Kevin T Huang; John Gallis; Yuliya Lokhnygina; Beth Parente; Patrick Hickey; Dennis A Turner; Shivanand P Lad Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: Vincent J J Odekerken; Teus van Laar; Michiel J Staal; Arne Mosch; Carel F E Hoffmann; Peter C G Nijssen; Guus N Beute; Jeroen P P van Vugt; Mathieu W P M Lenders; M Fiorella Contarino; Marieke S J Mink; Lo J Bour; Pepijn van den Munckhof; Ben A Schmand; Rob J de Haan; P Richard Schuurman; Rob M A de Bie Journal: Lancet Neurol Date: 2012-11-16 Impact factor: 44.182
Authors: Michael S Okun; Bruno V Gallo; George Mandybur; Jonathan Jagid; Kelly D Foote; Fredy J Revilla; Ron Alterman; Joseph Jankovic; Richard Simpson; Fred Junn; Leo Verhagen; Jeff E Arle; Blair Ford; Robert R Goodman; R Malcolm Stewart; Stacy Horn; Gordon H Baltuch; Brian H Kopell; Frederick Marshall; Delea Peichel; Rajesh Pahwa; Kelly E Lyons; Alexander I Tröster; Jerrold L Vitek; Michele Tagliati Journal: Lancet Neurol Date: 2012-01-11 Impact factor: 44.182
Authors: Houtan A Taba; Samuel S Wu; Kelly D Foote; Chris J Hass; Hubert H Fernandez; Irene A Malaty; Ramon L Rodriguez; Yunfeng Dai; Pamela R Zeilman; Charles E Jacobson; Michael S Okun Journal: J Neurosurg Date: 2010-09-17 Impact factor: 5.115
Authors: Francesco Vergani; Andrea Landi; David Pirillo; Roberto Cilia; Angelo Antonini; Erik P Sganzerla Journal: World Neurosurg Date: 2010-04 Impact factor: 2.104
Authors: Steven Falowski; Yinn Cher Ooi; Adam Smith; Leonard Verhargen Metman; Roy A E Bakay Journal: Stereotact Funct Neurosurg Date: 2012-06-05 Impact factor: 1.875
Authors: W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl Journal: N Engl J Med Date: 2013-02-14 Impact factor: 91.245
Authors: Kevin T Stroupe; Frances M Weaver; Lishan Cao; Dolores Ippolito; Brandon R Barton; Inger E Burnett-Zeigler; Robert G Holloway; Barbara G Vickrey; Tanya Simuni; Kenneth A Follett Journal: Mov Disord Date: 2014-09-15 Impact factor: 10.338
Authors: Brett E Youngerman; Evan F Joiner; Xianling Wang; Jingyan Yang; Mary R Welch; Guy M McKhann; Jason D Wright; Dawn L Hershman; Alfred I Neugut; Jeffrey N Bruce Journal: J Neurooncol Date: 2019-12-13 Impact factor: 4.130
Authors: Karlo J Lizarraga; Corneliu C Luca; Antonio De Salles; Alessandra Gorgulho; Anthony E Lang; Alfonso Fasano Journal: Surg Neurol Int Date: 2017-10-24
Authors: Chengyuan Wu; Sean J Nagel; Rahul Agarwal; Monika Pötter-Nerger; Wolfgang Hamel; Ashwini D Sharan; Allison T Connolly; Binith Cheeran; Paul S Larson Journal: Front Neurol Date: 2021-12-02 Impact factor: 4.003
Authors: Katja Engel; Torge Huckhagel; Alessandro Gulberti; Monika Pötter-Nerger; Eik Vettorazzi; Ute Hidding; Chi-Un Choe; Simone Zittel; Hanna Braaß; Peter Ludewig; Miriam Schaper; Kara Krajewski; Christian Oehlwein; Katrin Mittmann; Andreas K Engel; Christian Gerloff; Manfred Westphal; Christian K E Moll; Carsten Buhmann; Johannes A Köppen; Wolfgang Hamel Journal: PLoS One Date: 2018-08-02 Impact factor: 3.240